Peptide Schedule
Dermorphin7 residuesYAFGYPSEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Dermorphin Dosage Calculator

Healing & RecoveryInjectionResearch~1.3 minutes half-life

Dermorphin is a naturally occurring heptapeptide (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated in 1981 from the skin secretions of South American tree frogs of the genus Phyllomedusa, particularly Phyllomedusa sauvagei and Phyllomedusa bicolor.

Potent analgesia at sub-microgram doses in preclinical modelsHigh selectivity for mu-opioid receptors with >1000-fold preference over delta and kappa subtypesSlower development of analgesic tolerance compared to morphine in animal studiesLess intense withdrawal syndrome relative to morphine at equianalgesic doses1 weeks on / 4 weeks off

50mcg · Single dose

100500
10.0 units
100 units (1mL)
Concentration
500
mcg/mL
Draw Volume
0.100
mL
Syringe Units
10.0
units
Doses / Vial
20
doses

Summary: Add 2mL BAC water to your 1mg vial. Draw to 10.0 units on a U-100 syringe for a 50mcg dose. This vial will last 20 doses.

Cycle Planner

Subcutaneous or Intravenous. Typical beginner frequency: single dose.

Dermorphin Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~1.3 minutes (plasma); 45 minutes terminal elimination (IV)
50%25%12.5%100%75%50%25%0%01m3m4m5m7mTime after injectionDose remaining
After 1 half-life (1m): 50% remainsAfter 2 half-lives (3m): 25% remainsAfter 3 half-lives (4m): 12.5% remains
At a 100mcg dose: 50% = 50mcg remaining after 1m. Recommended frequency: Single dose.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Dermorphin Dosing Protocol

LevelDose / InjectionFrequency
Beginner50mcgSingle dose
Moderate100mcgSingle dose
Aggressive200mcgSingle dose

Note: Dermorphin is a Schedule-restricted mu-opioid agonist peptide with 30-40x the potency of morphine. It is banned by the Association of Racing Commissioners International (ARCI) as a Class I substance in equine competition and has been at the center of multiple horse racing doping scandals since 2011. This peptide carries high abuse and dependence potential. In many jurisdictions it is treated as a controlled substance or regulated analog of morphine. It is presented here strictly for academic and research reference. Dermorphin is NOT appropriate for self-administration, performance enhancement, or recreational use. Researchers should verify local regulations before procurement.

About Dermorphin

Dermorphin is a naturally occurring heptapeptide (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated in 1981 from the skin secretions of South American tree frogs of the genus Phyllomedusa, particularly Phyllomedusa sauvagei and Phyllomedusa bicolor. It is one of the most potent naturally occurring opioid peptides known, exhibiting 30-40 times greater analgesic potency than morphine and binding mu-opioid receptors with a Ki of approximately 0.2-0.5 nM. The presence of a D-alanine residue at position 2 — a rare feature in vertebrate peptides — confers resistance to enzymatic degradation and restricts the peptide backbone into a conformation optimal for mu-receptor activation. The D-Ala2 residue is biosynthesized from L-alanine in the precursor protein through a post-translational isomerization unique to amphibian skin peptides. In preclinical studies, dermorphin administered intrathecally was 3,000-5,000 times more active than spinal morphine in standard nociceptive assays. When injected intracerebroventricularly in rodents, it produced potent dose-dependent analgesia reversed by naloxone, confirming opioid receptor-mediated activity. Interestingly, dermorphin appears to induce slower tolerance development and less intense naloxone-precipitated withdrawal compared to morphine, which initially generated interest for potential clinical applications. A 2018 review explored its possible role in intrathecal palliative care for oncological pain, though this remains entirely theoretical. Despite these properties, dermorphin has never been approved for human clinical use in any jurisdiction. Its primary notoriety comes from illicit use in horse racing. Dermorphin was undetectable by standard equine drug screens until 2011, when intelligence from North American tracks led to the development of LC-MS/MS detection methods. Approximately 30 positive cases were identified in Oklahoma and Louisiana, triggering industry-wide regulatory action. WARNING: Dermorphin is a potent opioid agonist with high abuse and addiction potential. It produces respiratory depression, physical dependence, and can be lethal in overdose. It is classified as a controlled or banned substance in multiple jurisdictions worldwide.

Frequently Asked Questions